Marie Thibault
Stock Analyst at BTIG
(4.08)
# 546
Out of 5,024 analysts
82
Total ratings
56%
Success rate
12.08%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Reiterates: Buy | $145 | $129.45 | +12.01% | 13 | Oct 15, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $127 → $132 | $97.71 | +35.09% | 12 | Oct 1, 2025 | |
| MASI Masimo | Reiterates: Buy | $198 | $148.56 | +33.28% | 4 | Sep 11, 2025 | |
| EMBC Embecta | Reiterates: Buy | $25 | $13.88 | +80.12% | 3 | Sep 5, 2025 | |
| OBIO Orchestra BioMed Holdings | Downgrades: Neutral | n/a | $3.66 | - | 2 | Aug 20, 2025 | |
| ATRC AtriCure | Maintains: Buy | $58 → $52 | $37.03 | +40.43% | 7 | Apr 30, 2025 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $312.45 | -13.59% | 4 | Nov 8, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $44.86 | +44.90% | 8 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $48.58 | +130.55% | 1 | Sep 10, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $65.41 | +83.46% | 7 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.58 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.38 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $11.32 | +76.68% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $175.67 | -20.31% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.81 | +286.74% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.04 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.44 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $290.00 | -97.93% | 1 | Apr 9, 2020 |
Abbott Laboratories
Oct 15, 2025
Reiterates: Buy
Price Target: $145
Current: $129.45
Upside: +12.01%
Boston Scientific
Oct 1, 2025
Maintains: Buy
Price Target: $127 → $132
Current: $97.71
Upside: +35.09%
Masimo
Sep 11, 2025
Reiterates: Buy
Price Target: $198
Current: $148.56
Upside: +33.28%
Embecta
Sep 5, 2025
Reiterates: Buy
Price Target: $25
Current: $13.88
Upside: +80.12%
Orchestra BioMed Holdings
Aug 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.66
Upside: -
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $58 → $52
Current: $37.03
Upside: +40.43%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $312.45
Upside: -13.59%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $44.86
Upside: +44.90%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $48.58
Upside: +130.55%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $65.41
Upside: +83.46%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.58
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.38
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $11.32
Upside: +76.68%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $175.67
Upside: -20.31%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.81
Upside: +286.74%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.04
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.44
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $290.00
Upside: -97.93%